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ARTICLE

Rare variants in KDR, encoding VEGF Receptor 2, are
associated with tetralogy of Fallot
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Vincent M. Christoffels2, Alex V. Postma2,25,38 ✉ and Connie R. Bezzina1,38 ✉
PURPOSE: Rare genetic variants in KDR, encoding the vascular endothelial growth factor receptor 2 (VEGFR2), have been reported
in patients with tetralogy of Fallot (TOF). However, their role in disease causality and pathogenesis remains unclear.
METHODS: We conducted exome sequencing in a familial case of TOF and large-scale genetic studies, including burden testing,
in >1,500 patients with TOF. We studied gene-targeted mice and conducted cell-based assays to explore the role of KDR genetic
variation in the etiology of TOF.
RESULTS: Exome sequencing in a family with two siblings affected by TOF revealed biallelic missense variants in KDR. Studies in
knock-in mice and in HEK 293T cells identiﬁed embryonic lethality for one variant when occurring in the homozygous state, and a
signiﬁcantly reduced VEGFR2 phosphorylation for both variants. Rare variant burden analysis conducted in a set of 1,569 patients of
European descent with TOF identiﬁed a 46-fold enrichment of protein-truncating variants (PTVs) in TOF cases compared to controls
(P = 7 × 10-11).
CONCLUSION: Rare KDR variants, in particular PTVs, strongly associate with TOF, likely in the setting of different inheritance
patterns. Supported by genetic and in vivo and in vitro functional analysis, we propose loss-of-function of VEGFR2 as one of the
mechanisms involved in the pathogenesis of TOF.
Genetics in Medicine (2021) 23:1952–1960; https://doi.org/10.1038/s41436-021-01212-y

INTRODUCTION
Tetralogy of Fallot (TOF) is the most common form of cyanotic
congenital heart defect (CHD).1 Although TOF can present in
combination with extracardiac defects, in the majority of cases it
presents as an isolated defect.2 An increased risk of CHD among
ﬁrst-degree relatives and offspring of TOF patients3,4 provides
evidence for a genetic contribution to the disease etiology. A

microdeletion on chromosome 22q11.2 is the most common
genetic abnormality identiﬁed in patients with TOF, accounting for
~15% of cases.5 In addition, several other genes, mainly encoding
cardiac transcription factors,6,7 have been implicated in TOF,
although these account for a minority of patients, and the majority
of cases remain genetically elusive. Over the last few years,
dysregulated vascular endothelial growth factor (VEGF) signaling
h-
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Fig. 1 Identiﬁcation of compound heterozygous KDR variants in a family with tetralogy of Fallot (TOF). (a) Pedigree of index family. The
two affected children are marked with black symbols, the unaffected parents and sibling with white symbols. Genotypes are shown beneath.
(b) Echocardiographic images of II-1 before cardiac surgery. 1: Parasternal long-axis view showing the large malalignment ventricular septal
defect (VSD) (*) and the overriding of the aorta. 2: Four chamber view showing the VSD. 3: Short-axis view of the right ventricular outﬂow tract
(RVOT), the dysplastic pulmonary valve (arrow) and dilated main pulmonary artery. 4: Color Doppler image showing turbulent ﬂow (yellowgreen) over the dysplastic valve consistent with a signiﬁcant stenosis. 5: Detail of the RVOT, dysplastic pulmonary valve, and dilated PA. Note
the dysplastic valve leaﬂets and small annulus. (c) Sanger sequencing chromatograms conﬁrming a compound heterozygous inheritance in
the two affected children. (d) Conservation of glycine residues at amino acid position 345 and 537 across species. (e) Location of KDR-p.
(Gly345Trp) and KDR-p.(Gly537Arg) on the protein VEGFR2 subdomains are based on Roskoski.20 Ao aorta, AoA aortic arch, APV absent
pulmonary valve, LA left atrium, LV left ventricle, PA pulmonary artery, PV pulmonary valve, RA right atrium, RV right ventricle.

as been implicated in the pathogenesis of TOF. Exome sequencing
studies have provided robust evidence that dominant, mainly
truncating, pathogenic variants in FLT4, encoding VEGF receptor 3
(VEGFR3), are an important genetic cause of TOF.8,9 Furthermore, a
candidate gene study10 identiﬁed rare variants in other VEGF
signaling genes, including KDR, which encodes VEGFR2.11 Yet the
causal role of rare variants in this gene has not been deﬁnitively
established for CHD.
We conducted exome sequencing in a family with two children
affected by TOF and identiﬁed biallelic missense variants in KDR.
We subsequently conducted a large-scale genetic study in
patients with TOF, including burden testing, and studies in
gene-targeted mice and cell-based assays, to further explore the
prevalence and nature of KDR genetic variation in patients with
TOF and possible mechanisms leading to the etiology of TOF.

MATERIALS AND METHODS
A detailed description of the methods is available in the Online
Supplemental Methods.
Genetics in Medicine (2021) 23:1952 – 1960

Genetic analysis and knock-in mouse model of index family with
tetralogy of Fallot
We performed exome sequencing on DNA from two siblings of Moroccan
descent affected by TOF with suspected recessive inheritance. Mouse lines
harboring variants orthologous to the two KDR variants identiﬁed in the
index family were generated by CRISPR/Cas9 targeting at Cyagen (Santa
Clara, CA 95050-2709, USA).

VEGFR2 phosphorylation assay
VEGFR2 phosphorylation status was assessed by western blot in yolk sac
cells from knock-in mice and transfected HEK 293T cells. Values were
compared to wild-type values by two-sided t-test per condition. A p value
< 0.05 was considered signiﬁcant.

Additional patients with rare KDR variants
Patients with TOF were selected based on one of the following criteria,
either (1) complex TOF, deﬁned as TOF with absent pulmonary valve
syndrome, pulmonary atresia, double outlet right ventricle, or with aortic
arch abnormalities; or (2) TOF with a positive family history of CHD or (3)
TOF patients of Moroccan descent. Patients from categories 1 and 2 were
derived from the Dutch national biobank of adult patients with CHD

D. Škorić-Milosavljević et al.

1954
(current ages 17 and 7 years, respectively). Both parents (I-1 and
I-2) and the unaffected sister (II-2) had normal echocardiograms
and were healthy.
Exome sequencing, performed in II-1 and II-3, revealed 85 rare
(minor allele frequency [MAF] < 0.1%) nonsynonymous or splice
site variants that were shared among the two affected patients,
none of which were homozygous. We excluded the presence of
rare variants in a curated set of TOF genes8 (n = 77; Supplementary table 3). Because of a suspected recessive inheritance in this
family, we prioritized biallelic variants. Two genes harbored
multiple rare variants. After testing the variants in the parents,
only one set of Sanger sequencing–validated compound heterozygous variants in KDR remained: KDR-p.(Gly345Trp) and KDR-p.
(Gly537Arg) (Supplementary table 4). These variants were present
in the two affected siblings in the compound heterozygous state,
and were each inherited from an unaffected parent (Fig. 1c). The
unaffected sister did not carry either KDR variant. KDR-p.
(Gly345Trp) and KDR-p.(Gly537Arg) were not found in an internal
data set of 390 controls of Moroccan descent or in any of the
publicly available reference databases, including 3,065 individuals
from North Africa and the Middle East in ﬁve population genetic
data sets (Supplemental table 5). They were predicted to be
deleterious by the in silico prediction tools SIFT and PolyPhen and
had high CADD scores (35 and 34). The variants were located in
the extracellular immunoglobulin(Ig)-like domains 4 and 5 of
VEGFR2, and the affected residues were evolutionarily conserved
(Fig. 1d, e).
The only other gene harboring multiple variants was COL5A2.
Although these variants were shared by the affected patients, they
were proven to be in cis, inherited from the unaffected father
(Supplementary table 4).

(CONCOR) or recruited at the Amsterdam UMC (Netherlands) and at the
Boston Children’s Hospital (USA). Patients from category 3 were recruited
at the University Hospital of Fez (Morocco). KDR coding and copy-number
variants were screened by Sanger sequencing and quantitative polymerase
chain reaction (qPCR) respectively. In addition, we submitted KDR to the
GeneMatcher database12 and considered both patients with CHD as well as
patients with other phenotypes.

Rare variant association analysis
We compared the burden of rare KDR variants in patients of European
descent with (1) unselected TOF (primary analysis) or (2) patients with any
type of CHD other than TOF (secondary analysis; these comprised a broad
spectrum of CHDs, varying from mild to severe defects, described in detail
elsewhere9,13) and controls. Cases were drawn from four different CHD
cohorts for which exome or genome sequence data was previously
generated.8,9,13,14 The non-Finnish European (NFE) subset of gnomAD v2
with exome data (gnomAD-NFE; n = 56,885)15 was used as control data set.
We assessed rare variants in the canonical KDR transcript
(ENST00000263923) in two different categories: protein-truncating variants
(PTVs, i.e., nonsense, frameshift, and splice site variants) and missense
variants. In addition, we analyzed the missense variants separately in ﬁve
different domains of VEGFR2 (Supplementary table 1). Burden comparisons
were performed using Fisher’s exact test. We applied a stringent
Bonferroni corrected p value of < 0.007 (i.e., 0.05/7 tests) as signiﬁcance
threshold.

RESULTS
Familial tetralogy of Fallot with biallelic KDR variants
The index family is a nonconsanguineous family of Moroccan
descent with two children affected by a severe and complex form
of TOF (Fig. 1a). Patient II-1 was diagnosed with a severe type of
TOF, consisting of absent pulmonary valve syndrome and double
outlet right ventricle (Fig. 1b). Patient II-3 was diagnosed with TOF
with a severely hypoplastic pulmonary valve and a double outlet
right ventricle, and a right-sided aortic arch. Detailed phenotypes
are provided in Supplementary table 2.
There was no evidence of facial dysmorphisms, extracardiac
manifestations, or neurodevelopmental delay in either child
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with KDR-p.(Gly537Arg). n = 4 for each condition. *Standard two-sided t-test p < 0.05 compared to WT; **p < 0.01 compared to WT.
Representative western blot can be found as Supplemental ﬁgure S1B.

[Gly345Trp]) and Kdr-p.(Gly535Arg) (orthologous to KDR-p.
[Gly537Arg]), respectively. Heterozygous mice (KdrG347W/+ and
KdrG535R/+) were born at normal Mendelian ratios and their hearts
were morphologically indistinguishable from control littermates.
This was also the case for compound heterozygous mice
(KdrG347W/G535R) and mice homozygous for the Kdr-p.(Gly347Trp)
variant (KdrG347W/G347W) (Fig. 2a and Supplementary table 6).
However, we were unable to recover any mice homozygous for
the Kdr-p.(Gly535Arg) variant (KdrG535R/G535R) at birth (Supplementary table 7), suggesting that this variant may be embryonically
lethal in the homozygous state. Previous studies have demonstrated that Kdr knockout animals die between embryonic day (E)
8.5 and E9.5 from severe vascular and hematopoietic abnormalities.16 Therefore, to determine whether KdrG535R/G535R mice mimic
null animals, we examined KdrG535R/G535R embryos at E9.5.
Although at this stage we found homozygous mice at normal
Mendelian ratios (Supplementary table 7), homozygous mutants
were smaller and paler than wild-type littermates with overall
apparent necrosis and impaired endothelial development (Fig. 2b).
Analysis of histological sections revealed an enlarged pericardial
cavity in KdrG535R/G535R embryos (Fig. 2c). Overall, the phenotype of
KdrG535R/G535R mice mimicked that of Kdr null mice,16 thus
revealing that homozygosity of the Kdr-p.(Gly535Arg) variant has
severe developmental consequences.
We next investigated the subcellular localization of VEGFR2 in
endocardial tissue of E10.0 KdrG535R/+ and KdrG535R/G535R mice.
Genetics in Medicine (2021) 23:1952 – 1960

VEGFR2 signaling is highly active at this stage.16 Immunoﬂuorescent staining of embryonic sections revealed VEGFR2 aggregation in the cytoplasm of endocardial cells in mutant embryos
(KdrG535R/+ and KdrG535R/G535R) that was largely absent in wild-type
littermates (Fig. 2d), where VEGFR2 predominantly localized to cell
membrane.
Familial KDR missense variants cause reduced VEGFR2
phosphorylation
In an effort to shed light on the biological mechanisms of the two
KDR variants of the index family, we examined the phosphorylation of VEGFR2 at Tyr1175, one of its major phosphorylation sites17
and crucial for the recruitment of proteins in the signaling cascade
downstream of VEGFR2.17,18 HEK 293T cells heterologously
expressing the two identiﬁed variants or wild-type KDR (control)
were stimulated with VEGF165. Western blot analysis on protein
isolates using an antibody directed toward VEGFR2 showed two
equally intense bands of the expected weight in cells expressing
the wild-type VEGFR2. However, the lower band, representing
unphosphorylated VEGFR2, was consistently and signiﬁcantly
more intense in cells expressing mutant VEGFR2, particularly
those expressing the KDR-p.(Gly537Arg) variant and those coexpressing KDR-p.(Gly345Trp) and KDR-p.(Gly537Arg). The latter
condition models the compound heterozygous state of the two
affected patients from the index family (Fig. 3a). Western blot
analysis with p-VEGFR2 antibody detected one major band at the
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Fig. 4 Schematic diagram of VEGFR2 with all variants identiﬁed in tetralogy of Fallot (TOF) patients. Location of rare KDR variants
identiﬁed in patients with TOF (index family and 1,653 TOF probands). Variants are split into missense variants (black) and protein-truncating
variants (PTVs) (red). Highlighted are the two variants identiﬁed in the index family, KDR-p.(Gly345Trp) and KDR-p.(Gly537Arg), and KDR-p.
(Val219Ala) and KDR-p.(Thr442Met), that were functionally tested. Domains marked as I–VII represent the Ig-like domains 1 to 7. The
transmembrane domain (gray box) separates the extracellular domain (left) of the intracellular domain (right). VEGFR2 subdomains are based
on Roskoski20.
Table 1.

Results burden test in patients with tetralogy of Fallot (TOF) (FAF < 0.01%).

Variant type

Protein domain

Cases: N variants/total N

Controls: N variants/total N

Fold enrichment

P value

PTV

All

9/1,569

7/56,728

46

7 × 10-11

Missense

All

27/1,569

791/56,721

1.2

0.28

All extracellular

19/1,569

452/56,687

1.5

0.08

Ligand binding

7/1,569

116/56,791

2.2

0.049

Ig-like 4-7

8/1,569

256/56,711

1.1

0.70

Protein kinase

3/1,569

122/56,722

0.9

1

All intracellular

8/1,569

339/56,722

0.9

0.87

Statistically signiﬁcant p values after correction for multiple testing are highlighted in bold (Fisher’s exact test p < 0.007).
FAF ﬁltering allele frequency, PTV protein-truncating variant.

expected weight (Fig. 3b), which had a signiﬁcantly lower intensity
for both variants expressed separately (40% and 80% reduction
compared to wild-type for KDR-p.[Gly345Trp] and KDR-p.
[Gly537Arg], respectively) and for the double mutant (60%
reduction compared to wild type, P = 0.003; Fig. 3b). Similarly,
western blot analysis of yolk sac cells from knock-in mouse
embryos showed a seemingly modest reduction of p-VEGFR2 in
KdrG347W/G347W mice, but a pronounced clear shift toward
decreased relative phosphorylated VEGFR2 in KdrG535R/+,
KdrG535R/G535R, and KdrG347W/G535R mice (Fig. 3c). Taken together,
these data suggest that both variants cause decreased VEGFR2
phosphorylation at position Tyr1175. In line with the observed
embryonic mortality and morphological phenotype of KdrG535R/
G535R
mice, decreased VEGFR2 phosphorylation at position Tyr1175
was most pronounced for KDR-p.(Gly537Arg) in HEK 293T cells and
for the orthologous Kdr-p.(Gly535Arg) in mouse yolk sac cells.
Collectively, the genetic data from the family and the
data obtained in mice and in vitro support a role for the two
rare KDR missense variants in the index family, in which
the functional effects of the KDR-p.(Gly537Arg) variant are
more severe compared to those of KDR-p.(Gly345Trp). A summary
of the characteristics of both variants is given in Supplementary
table 8.
KDR variants in different patient sets
Based on the observation in the index family, we screened for
coding variants and copy-number variants in KDR, using Sanger
sequencing and qPCR respectively, in 82 patients with TOF who
met at least one of the following criteria: (1) complex TOF, (2)
positive family history of CHD, or (3) Moroccan descent. We
identiﬁed a rare heterozygous missense variant (KDR-p.
[Thr442Met], MAF gnomAD v2: 2 × 10-5) in one patient from the
CONCOR biobank, with complex TOF, i.e., TOF and absent
pulmonary valve syndrome (Supplementary table 9). Information

about ethnicity was not collected, and unfortunately both the
patient and her parents were unavailable for follow-up or genetic
testing. Like the KDR-p.(Gly537Arg) variant from the index family,
this variant was also located in Ig-like domain 5 (Fig. 4). Similar to
the variants from the index family, western blot analysis with the
p-VEGFR2 antibody demonstrated signiﬁcantly reduced p-VEGFR2
for KDR-p.(Thr442Met) compared to wild type KDR (p < 0.001,
Fig. 3d). No other coding variants or copy-number variants in KDR
were detected in the remaining patients.
Through GeneMatcher we identiﬁed two more patients with
complex TOF and a rare heterozygous variant in KDR, both PTVs:
KDR-p.(R819*) and KDR-c.2614 + 1G>A (Fig. 4, Supplementary
table 10). One of these was de novo, while the other PTV was
inherited from the father who had three strokes stemming from
an underlying autoimmune disease (suggested Takayasu syndrome). Moreover, these patients also had extracardiac abnormalities (Supplementary table 10).
In addition, we identiﬁed three patients with other types of
CHD (with and without extracardiac abnormalities) and a
heterozygous missense variant in KDR (de novo in two patients
and inherited in the third), and two patients with a de novo KDR
variant (one missense and one PTV, both heterozygous) had a
noncardiac phenotype (Supplementary table 10). This suggests
that rare KDR variants might also be associated with other
phenotypes.
Protein truncating variants are signiﬁcantly enriched in patients
with TOF
We next explored the causal role of rare KDR variants in TOF, by
comparing the burden of rare variants in TOF patients with
controls. A total of 1,569 patients with unselected TOF of
European descent were drawn from different published8,9,13,14
and unpublished cohorts of patients with CHD (Supplementary
table 11). Controls consisted of 56,885 individuals of non-Finnish
Genetics in Medicine (2021) 23:1952 – 1960
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European descent drawn from a reference population (gnomADNFE v215). Rare KDR variants with a population maximum
ﬁltering allele frequency (FAF) < 0.01% (gnomAD v315) were
considered. As expected, we saw no difference in the frequency
of synonymous variants between cases and controls (Supplementary table 12). We identiﬁed a total of 36 protein altering
variants, 9 PTVs, and 27 missense variants (Fig. 4 and
Supplementary table 9), in 35 patients with TOF. One patient
had two different KDR missense variants (KDR-p.[Gly23Ser] and
KDR-p.[Thr446Met]), but we could not assess compound
heterozygosity due to lack of parental samples. The remaining
34 patients carried heterozygous KDR variants. In total, we
identiﬁed rare KDR variants in 2.3% of patients with TOF.
Parental samples were available for 8 of 35 patients and showed
all 8 variants were inherited. There was a signiﬁcant excess (46fold enrichment) of PTVs in TOF cases compared to gnomADNFE controls (9 PTVs in 1,569 TOF cases versus 7 PTVs in 56,699
gnomAD-NFE controls; P = 7 × 10-11, Table 1). On the other
hand, we detected no statistical enrichment of rare missense
variants in patients with TOF compared to gnomAD-NFE
controls (Table 1). Restricting the analysis to missense variants
with a high in silico deleteriousness score (CADD > 20) or to
ultrarare variants (FAF < 0.001%) did not inﬂuence the result.
Because VEGFR2 is composed of different domains (Fig. 4 and
Supplementary table 1),19,20 we next considered these distinct
VEGFR2 subdomains separately in burden testing (Table 1). We
observed a higher, though not statistically signiﬁcant, burden of
rare missense variants in the extracellular domain in patients
with TOF compared to controls (19 variants in 1,569 TOF cases
vs. 452 variants in 56,687 gnomAD-NFE controls; P = 0.08,
Table 1 and Supplementary table 12). This signal seemed to
be driven by variants in the ligand binding domain (7 variants in
1,569 TOF cases vs. 116 variants in 56,791 gnomAD-NFE controls,
P = 0.04, Table 1), with two variants found in multiple patients
(KDR-p.[Val159Met] in two patients and KDR-p.[Val219Ala] in
three patients). Western blot analysis with the p-VEGFR2
antibody demonstrated a signiﬁcantly reduced p-VEGFR2 for
KDR-p.(Val219Ala) compared to wild-type KDR (p < 0.004, Fig. 3d);
KDR-p.(Val159Met) was not tested.
Conversely, we did not identify any PTVs in patients with other
types of CHD, neither did we observe an enrichment of missense
variants in this group of patients in any of the subdomains (n =
2,312, Supplementary table 12).
DISCUSSION
We identiﬁed compound heterozygous rare missense variants in
KDR in a family with two siblings affected by a severe, complex
form of TOF. Subsequent studies conducted in knock-in mice and
cell-based assays showed signiﬁcant diminished VEGFR2 autophosphorylation. In addition, the higher burden of PTVs in the 1,569
patients with TOF compared to controls further supports a loss-offunction mechanism. In total, 0.6% of patients with TOF in this
study carried a PTV. The suggestive enrichment of rare missense
variants in the extracellular domain of VEGFR2 in patients with
TOF, together with the signiﬁcant reduction in VEGFR2 phosphorylation we showed for multiple missense variants from this
domain, suggests that disruption of residues within the extracellular domain of VEGFR2 might play a role in the pathogenesis
of TOF.
The patients from the index family in this study carried biallelic
variants in KDR. The observations made in knock-in mice and in
heterologous studies in vitro support a causal role for both
missense variants and may suggest a recessive inheritance model.
Although we identiﬁed one additional patient with two different
rare KDR missense variants, compound heterozygosity could not
be conﬁrmed in this patient due to lack of parental samples. KDR
variants in all other patients in this study, as well as in a previously
Genetics in Medicine (2021) 23:1952 – 1960

published study,10 were heterozygous. In some of these patients,
the de novo occurrence of these variants provides support for
dominant inheritance. On the other hand, the observation that
some individuals inherited the putatively pathogenic variant from
an unaffected parent points to reduced penetrance and a more
complex inheritance, a phenomenon that can also not be
excluded in the index family. Taken together, our data suggest
that rare KDR variants may lead to TOF in the context of different
inheritance paradigms that likely vary from monogenic to
complex (oligogenic or polygenic).
We provide strong evidence that PTVs in KDR contribute to
the pathogenesis of TOF. PTVs were approximately 45 times more
prevalent among TOF cases compared to controls. In total we
identiﬁed 11 PTVs in KDR in patients with TOF, not overlapping the
two previously reported PTVs in patients with TOF.10 Although 8 of
the 11 identiﬁed PTVs (73%) were located in the intracellular
domain, these numbers are too small to make any statement
about nonrandom distribution in TOF cases. Interestingly, we did
not ﬁnd any PTVs among a set of 2,312 patients with CHDs other
than TOF, which may suggest that loss of function of this gene
speciﬁcally predisposes to TOF within the spectrum of CHD. Of
note, PTVs in KDR were recently also reported in patients with
pulmonary arterial hypertension (PAH),21,22 although none of the
PAH cases were reported to have CHD. What determines why
some PTVs lead to TOF, while others might cause PAH, remains
unclear.
Though not statistically signiﬁcant, we observed a higher
proportion of rare KDR missense variants in the extracellular
domain of VEGFR2 in patients with TOF. One of these variants,
KDR-p.(Val219Ala), was found in multiple patients and showed a
marked reduced effect on VEGFR2 phosphorylation. This was in
line with the KDR variants of the index family, and of a patient with
TOF and absent pulmonary valve syndrome (KDR-p.([Thr442Met]),
that were all located within the extracellular domain and
also exhibited signiﬁcantly reduced VEGFR2 phosphorylation.
Similarly, missense variants in FLT4, encoding for VEGFR3,
previously reported in patients with TOF, were primarily located
in the extracellular domain.8,10 Clearly, larger studies are needed
to conﬁrm whether the extracellular domain is indeed speciﬁcally
enriched in rare missense variants, as well as to explore
differences in phenotype based on variant location in the protein.
In addition, future studies should also assess whether there are
phenotypic differences between patients with amorphic versus
hypomorphic KDR variants.
The importance of VEGFR2 in heart development has long been
established. While Kdr KO mice die early during development,
conditional deletion of mouse Kdr in the endothelium (using an
endothelial-speciﬁc Cre driver) causes embryonic lethality at
E9.5–E10.5 associated with cardiac defects, including hypoplasia
of the outﬂow tract (OFT) and the right ventricle, and loss of the
endocardium,23 highlighting the role of VEGFR2 in OFT development. The second heart ﬁeld (SHF) is essential for formation of the
OFT and right ventricle,24 both regions of the heart affected in
TOF. Conditional deletion of Kdr in the Isl1 lineages, which
includes the SHF, while showing preserved endocardium, leads to
embryonic lethality at E14.5,23 supporting an important role of
VEGFR2 in cardiogenesis independent from its role in the
endocardium. The role of VEGFR2 in the SHF is further highlighted
by the presence of Vegfr2 expression in the pharyngeal mesoderm
at E8.5 and, at later stages, in (parts) of the SHF.25 Moreover, it was
shown that the Tbx1 transcription factor, essential during OFT
development, affects Vegfr2 expression in the SHF in vivo in
mouse embryos and that TBX1 favors a cardiac fate in VEGFR2
expressing cells.25 Given the above, we hypothesize that altered
VEGFR2 expression and/or function within the SHF could directly
or indirectly contribute to malformation of the OFT, and
therefore TOF.
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In an effort to provide evidence for causality of missense
variants in KDR and determine their mechanism of pathogenicity,
we engineered knock-in mouse lines harboring orthologues of the
two variants identiﬁed in the index family. Contrary to the index
family, where the disease phenotype was presumed to result from
biallelic inheritance, compound heterozygous knock-in mice (i.e.,
KdrG347W/G535R) were phenotypically normal. The lack of phenotype
in the double heterozygous knock-in mice could be due to genetic
background effects, a phenomenon that is ﬁrmly established for
CHD.26 Although KdrG347W/G347W exhibited no morphological
abnormalities, mice homozygous for the orthologous variant to
the familial KDR-p.(Gly537Arg) variant (KdrG535R/G535R) died during
embryonic development and recapitulate the phenotype of
constitutive Kdr knockout mice,16 underscoring the causality and
severity of this variant. The varying severity of these two variants
in mice in the homozygous state is reﬂected by the observed
differences in severity in their Tyr1175 (p-VEGFR2) phosphorylation defect. Similar to the phosphorylation data in the mouse, in
HEK 293T cells we observed a marked reduction in p-VEGFR2 in
cells co-expressing the two variants or expressing KDR-p.
(Gly537Arg) alone, while a milder decrease was seen in cells
expressing the KDR-p.(Gly345Trp) variant. In aggregate, these data
and the co-segregation data in the family support the concept
that both alleles may be necessary for the development of the
phenotype in the family, but contribute differentially to disease
susceptibility, with the KDR-p.(Gly537Arg) variant having a larger
effect than the KDR-p.(Gly345Trp) variant.
The extracellular domain of VEGFR2 is a critical part of the
protein as it harbors the VEGF binding domain, and initiates
receptor dimerization upon ligand binding.11 Furthermore,
homotypic receptor–receptor contacts between Ig-like domains
4 and 7 further stabilize these VEGFR2 dimers and are essential for
the exact positioning of the intracellular kinase domains,27,28
which
institute
protein
kinase
activation,
transautophosphorylation (among others on Tyr1175), and initiation
of signaling pathways. We suggest that the tested missense
variants in the extracellular domain, i.e., KDR-p.(Gly345Trp), KDR-p.
(Gly537Arg), KDR-p.(Val219Ala), and KDR-p.(Thr442Met), disturb
this sequence of events, likely leading to diminished autophosphorylation and receptor activation. At the same time, in normal
situations, ligand induced VEGFR2 activation stimulates the
recycling of the intracellular VEGFR2 pool,29 as well as exit of
newly synthesized VEGFR2 from the Golgi,30 thereby increasing
the fraction of VEGFR2 on the plasma membrane. The intracellular
accumulation of VEGFR2 that we observed for the KDR-p.
(Gly537Arg) variant could indicate that this variant may interfere
with this process. In turn, as receptors in intracellular vesicles are
not accessible for VEGF, abnormal accumulation might further
reduce the VEGFR2 phosphorylation levels. Regarding the KDR
PTVs, we expect most if not all PTVs detected in TOF patients to
result in nonsense-mediated decay (based on their location) and
haploinsufﬁciency. We hypothesize that such reduced levels of
VEGFR2 will impact on the total absolute amount of autophosphorylated VEGFR2, ultimately affecting proper function and
development. Indeed phosphorylation of VEGFR2 at Tyr1175 has
been shown to be essential for endothelial and hematopoietic
development during embryogenesis.31 Yet, despite our ﬁnding of
reduced autophosphorylation as a consequence of genetic
variation in KDR, the exact involvement of reduced autophosphorylation in pathogenesis of TOF remains to be studied. While
VEGFR2 signaling is extremely complex, and more than half a
dozen pathways are recognized,19 a possible link between
malfunctioning VEGFR2 phosphorylation and CHD comes from
the knowledge that Tyr1175 phosphorylation is important in
activation of the PLCϒ-ERK1/2 pathway17,18 and that disturbed
ERK1/2 signaling contributes to cardiac defects that comprise TOF
in vivo.32,33 Future studies are needed to address the exact

downstream pathways affected by decreased VEGFR2 Tyr1175
phosphorylation.
Limitations
Although we showed that the KDR variants in the index family are
absent from publicly available reference data sets and 390 internal
Moroccan controls, larger region-speciﬁc population genetic data
sets will be required to fully conﬁrm the rarity of the variants
detected in Moroccan patients. In this study we only focused on
rare variants in KDR and did not explore a multigenic inheritance.
We did not functionally test all variants identiﬁed in patients and
are therefore not able to conclude on their pathogenicity. We
used individuals from the gnomAD collection as a control data set
in the burden analysis. Although there are some inevitable
limitations to this approach, it has been shown to be successful in
other inherited cardiac disorders.34
Conclusion
In conclusion, our data supports a role for rare KDR variants in
pathogenesis of TOF through a loss-of-function mechanism. The
total yield of rare KDR (VEGFR2) variants in TOF patients in this
study (2.3%) is comparable to the previously reported yield of rare
FLT4 (VEGFR3) variants in patients with TOF. Taken together, the
ﬁndings in this study shed light on the role of VEGF signaling in
TOF and justify consideration of KDR screening in TOF patients in a
clinical diagnostic setting.
DATA AVAILABILITY
Available upon request.

Received: 27 December 2020; Revised: 2 May 2021; Accepted: 4
May 2021;
Published online: 10 June 2021
REFERENCES
1. Bailliard, F. & Anderson, R. H. Tetralogy of Fallot. Orphanet J. Rare Dis. 4, 2
(2009).
2. Egbe, A., Ho, D., Lee, S., Uppu, S. & Srivastava, S. Prevalence of congenital
anomalies in newborns with congenital heart disease diagnosis. Ann. Pediatr.
Cardiol. 7, 86 (2014).
3. Burn, J. et al. Recurrence risks in offspring of adults with major heart defects:
results from ﬁrst cohort of British collaborative study. Lancet. 351, 311–316
(1998).
4. Peyvandi, S. et al. Risk of congenital heart disease in relatives of probands with
conotruncal cardiac defects: an evaluation of 1,620 families. Am. J. Med. Genet. A.
164, 1490–1495 (2014).
5. Goldmuntz, E. et al. Frequency of 22q11 deletions in patients with conotruncal
defects. J. Am. Coll. Cardiol. 32, 492–498 (1998).
6. Yang, Y. Q. et al. GATA4 loss-of-function mutations underlie familial tetralogy of
Fallot. Hum. Mutat. 34, 1662–1671 (2013).
7. Goldmuntz, E., Geiger, E. & Benson, D. W. NKX2.5 mutations in patients with
tetralogy of fallot. Circulation. 104, 2565–2568 (2001).
8. Page, D. J. et al. Whole exome sequencing reveals the major genetic contributors
to non-syndromic tetralogy of Fallot. Circ. Res. 124, 553–563 (2018).
9. Jin, S. C. et al. Contribution of rare inherited and de novo variants in 2,871
congenital heart disease probands. Nat. Genet. 49, 1593–1601 (2017).
10. Reuter, M. S. et al. Haploinsufﬁciency of vascular endothelial growth factor related
signaling genes is associated with tetralogy of Fallot. Genet. Med. 21, 1001–1007
(2018).
11. Holmes, K., Roberts, O. L., Thomas, A. M. & Cross, M. J. Vascular endothelial growth
factor receptor-2: structure, function, intracellular signalling and therapeutic
inhibition. Cell. Signal. 19, 2003–2012 (2007).
12. Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching
tool for connecting investigators with an interest in the same gene. Hum. Mutat.
36, 928–930 (2015).
13. Sifrim, A. et al. Distinct genetic architectures for syndromic and nonsyndromic
congenital heart defects identiﬁed by exome sequencing. Nat. Genet. 48,
1060–1065 (2016).

Genetics in Medicine (2021) 23:1952 – 1960

D. Škorić-Milosavljević et al.

1959
14. Homsy, J. et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 350, 1262–1266 (2015).
15. Karczewski, K. J. et al. The mutational constraint spectrum quantiﬁed from variation in 141,456 humans. Nature. 581, 434–443 (2020).
16. Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1deﬁcient mice. Nature. 376, 62–66 (1995).
17. Takahashi, T., Yamaguchi, S., Chida, K. & Shibuya, M. A single autophosphorylation
site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma
and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768–2778 (2001).
18. Kroll, J. & Waltenberger, J. The vascular endothelial growth factor receptor KDR
activates multiple signal transduction pathways in porcine aortic endothelial
cells. J. Biol. Chem. 272, 32521–32527 (1997).
19. Koch, S., Tugues, S., Li, X., Gualandi, L. & Claesson-Welsh, L. Signal transduction by
vascular endothelial growth factor receptors. Biochem. J. 437, 169–183 (2011).
20. Roskoski, R. VEGF receptor protein-tyrosine kinases: structure and regulation.
Biochem. Biophys. Res. Commun. 375, 287–291 (2008).
21. Gräf, S. et al. Identiﬁcation of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat. Commun. 9, 1–16 (2018).
22. Eyries, M. et al. Familial pulmonary arterial hypertension by KDR heterozygous
loss of function. Eur. Respir. J. 55, 1902165 (2020).
23. Milgrom-Hoffman, M. et al. The heart endocardium is derived from vascular
endothelial progenitors. Development. 138, 4777–4787 (2011).
24. Xu, H. et al. Tbx1 has a dual role in the morphogenesis of the cardiac outﬂow
tract. Development. 131, 3217–3227 (2004).
25. Lania, G., Ferrentino, R. & Baldini, A. TBX1 represses vegfr2 gene expression and
enhances the cardiac fate of VEGFR2+ cells. PLoS One. 10, e0138525 (2015).
26. Rajagopal, S. K. et al. Spectrum of heart disease associated with murine and
human GATA4 mutation. J. Mol. Cell. Cardiol. 43, 677–685 (2007).
27. Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T. & Ballmer-Hofer, K. Structure of a
VEGF-VEGF receptor complex determined by electron microscopy. Nat. Struct.
Mol. Biol. 14, 249–250 (2007).
28. Hyde, C. A. C. et al. Targeting extracellular domains D4 and D7 of vascular
endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites.
Mol. Cell. Biol. 32, 3802–3813 (2012).
29. Gampel, A. et al. VEGF regulates the mobilization of VEGFR2/KDR from an
intracellular endothelial storage compartment. Blood. 108, 2624–2631 (2006).
30. Manickam, V. et al. Regulation of vascular endothelial growth factor receptor 2
trafﬁcking and angiogenesis by Golgi localized t-SNARE syntaxin 6. Blood. 117,
1425–1435 (2011).
31. Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N. & Shibuya, M. Essential role of
Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc.
Natl. Acad. Sci. U. S. A. 102, 1076–1081 (2005).
32. Araki, T. et al. Mouse model of Noonan syndrome reveals cell type- and
gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10, 849–857
(2004).
33. Krenz, M., Yutzey, K. E. & Robbins, J. Noonan syndrome mutation Q79R in Shp2
increases proliferation of valve primordia mesenchymal cells via extracellular
signal-regulated kinase 1/2 signaling. Circ. Res. 97, 813–820 (2005).
34. Mazzarotto, F. et al. Reevaluating the genetic contribution of monogenic dilated
cardiomyopathy. Circulation. 141, 387–398 (2020).

ACKNOWLEDGEMENTS
We gratefully acknowledge the patients and their families for participation. The
authors thank Sylvia Mantels and Lia C.J.M. Engelfriet-Rijk for their valuable work
recruiting patients and managing the CONCOR registry. We acknowledge the Labatt
Family Heart Centre Biobank, Hospital for Sick Children, funded by the Ted Rogers
Centre for Heart Research, for access to sequencing data. A subset of data used in this
study was generated by the Pediatric Cardiac Genomics Consortium (PCGC), under
the auspices of the National Heart, Lung, and Blood Institute (NHLBI)’s Bench to
Bassinet Program (dbGaP study accession: phs001194.v2.p2). The PCGC program is
funded by the NHLBI, National Institutes of Health, US Department of Health and
Human Services through grants UM1HL128711, UM1HL098162, UM1HL098147,
UM1HL098123, UM1HL128761, U01HL131003. This paper was not prepared in
collaboration with investigators of the PCGC, has not been reviewed and/or approved
by the PCGC, and does not necessarily reﬂect the opinions of the PCGC investigators
or the NHLBI.

C.R.B., D.S.-M., E.M.L., F.M.B., N.L., R.W., S.G.W., V.M.C. Project administration: A.V.P.,
C.R.B., D.S.-M. Resources: A.M.M., A. Rauch, A. Roberts, A.S., A.W., B.D.K., B.J.M., B.K.,
D.B., D.S.-M., D.Z., E.Z., F.V.Y.T, H.C.M., I.E.B., I.K., I.R., I.T., K.O., K.S., L.C., M.M., M.-P.H.,
N.A., N.A.B., P.J., P.K., S.A., S.A.B.C., S.E.S., S.H., S.M., T.P. Software: N.L. Supervision:
A.V.P., B.D.K., C.R.B., M.-P.H., S.M., V.M.C. Validation: A.V.P., F.M.B., R.W. Visualization:
A.V.P., D.S.-M., F.M.B., R.W., S.A.B.C. Writing—original draft: A.V.P., C.R.B., D.S.-M., F.M.B.,
S.A.B.C., V.M.C. Writing—review & editing: A.S., A.V.P., A.W., B.D.K., B.J.M., B.K., C.R.B.,
D.S.-M., E.M.L., F.M.B., F.V.Y.T, G.D., H.C.M., I.E.B., I.R., I.T., M.-P.H., N.L., P.J., P.K., R.L., R.W.,
S.A.B.C., S.E.S., S.G.W., S.M., V.M.C.

FUNDING
This work has been funded by research grants from the DHF (CVON project 2014-18
CONCOR-genes, to C.R.B. and V.M.C.), the CHF (to C.R.B.) and the PROCEED project,
ERA PerMed Joint Translational Call Initiative (to S.M., C.R.B., and M.-P.H.). C.R.B. is
funded by research grants from NWO (VICI fellowship, 016.150.610) and the Leducq
Foundation (17CVD02). V.M.C. is funded by the Leducq Foundation (14CVD01). The
work of E.M.L. is partly ﬁnanced by the NWO (VIDI-91718361) and the CVON RESCUED
project. S.M. holds the Heart and Stroke Foundation of Canada/Robert M Freedom
Chair in Cardiovascular Science. The work of P.K. and M.M. was supported in part by
the Division of Intramural Research of the NHGR. The work of I.T. and T.P. was
supported by GA4K at Children’s Mercy hospital. This work was supported by the
CNCHD with funding from the Federal Ministry of Education and Research (01GI0601
until 2014) and the DZHK (German Centre for Cardiovascular Research; as of 2015).
The work of F.V.Y.T. is ﬁnanced by a research grant from the DHF (E. Dekker grant
2014T053). Research reported in this publication was supported by the NCATS of the
NIH (TL1TR001880) and by the ITMT of the Perelman School of Medicine, University of
Pennsylvania (S.E.S). The content is solely the responsibility of the authors and does
not necessarily represent the ofﬁcial views of the NIH. B.D.K. is supported by a BHF
personal chair. S.G.W. is supported by the BHF. R.W. is supported by an ACS
fellowship. J.B. is funded by a senior clinical investigator fellowship of the FWOFlanders. H.C.M. was supported by a grant from NIH/NINDS (NS069605).

ETHICS DECLARATION
Human subjects: Most participants were ascertained via research studies. These
individuals gave consent to their research participation. This study was approved by
the Amsterdam University Medical Center Research Ethics Committee, the Northern
and Yorkshire Research Ethics Committee, the Hospital for Sick Children research
ethics board and the ethics committee of the Charité Universitätsmedizin Berlin
(#EA2/131/10). For samples from the CONCOR registry (https://concor.net/en/)
informed consent was obtained from all patients for collection of samples and data
for research including information about reporting of individual results and incidental
ﬁndings (PMID 16121765). For samples from the Heart Centre Biobank Registry
(https://theheartcentrebiobank.com/) informed consent was obtained from all
patients/parents/legal guardians for collection of samples and data for research
including sharing with internal and external researchers (PMID 23045559). The use of
samples from the German Competence Network for Congenital Heart Defects
(CNCHD)
(https://www.kompetenznetz-ahf.de/en/researchers/join-our-research/
national-register-biobank/) is based on a broad consent according to the principles
of the Declaration of Helsinki (PMID 27132144). Participants who were identiﬁed via
clinical diagnostics procedures (only GeneMatcher individuals) gave clinical consent
for testing using standard forms used locally at each site, and their permission for
anonymized inclusion in this publication. Mouse studies: Animal care and experiments
were in accordance with guidelines from the European Union, the Dutch government
and the Amsterdam University Medical Center (UMC) and were approved by the
Animal Experimental Committee of the Amsterdam UMC.
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